Company Overview More
Clarus Therapeutics Holdings, Inc. operates as a men's health specialty pharmaceutical company that focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for product to treat androgen-dependent inflammatory breast disease and certain forms of breast cancer. Clarus Therapeutics Holdings, Inc. was founded in 2003 and is based in Northbrook, Illinois.
CEO: Dudley Ph.D., Robert E.
Market: NASDAQ
Futu Hot List
USHKCN
Trade HeatSearch HeatNews Heat
SymbolLatest Price% Chg

Loading...

CRXT CLARUS THERAPEUTICS HLDGS INC

4.071-0.139-3.29%
Trading Session 10/28 13:08 ET
High
4.250
Open
4.160
Turnover
611.79K
Low
3.980
Prev.Close
4.210
Volume
149.92K
Market Cap
88.45M
P/E(TTM)
Loss
52Wk High
31.240
Shares
21.73M
P/E
Loss
52Wk Low
3.430
H Mkt Cap
13.82M
Bid-Ask Ratio
-25.00%
Historical High
31.240
H Shares
3.39M
Vol. Ratio
0.53
Historical Low
3.430
Dividend TTM
--
Div Yield TTM
--
P/B
-3.91
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
4.42%
Amplitude
6.41%
Avg Price
4.080
Min Trading Unit
1
Float Market Cap
13.82M
Bid-Ask Ratio
-25.00%
Historical High
31.240
Float
3.39M
Vol. Ratio
0.53
Historical Low
3.430
Dividend TTM
--
P/B
-3.91
Dividend LFY
--
Turnover Ratio
4.42%
Amplitude
6.41%
Avg Price
4.080
Min Trading Unit
1
Price Forecast

Loading...

News